Scientific article

The role of rituximab in the treatment of ANCA-associated vasculitides (AAV)

Published inSchweizerische medizinische Wochenschrift, vol. 145, w14103
Publication date2015

The antineutrophil cytoplasmic antibody (ANCA) associated vasculitides (AAV) are a group of primary vasculitides that affect predominantly small- to medium-sized blood vessels. AAV include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and eosinophilic granulomatosis with polyangiitis (EGPA). Disease severity is dictated by the location and extent of the blood vessels affected. If left untreated, systemic forms of AAV are often fatal. The advent of immunosuppressive therapy (cyclophosphamide plus glucocorticoids) has revolutionised the prognosis for patients with AAV, transforming the course of the disease from fatal to one that can be managed, though not without significant treatment-related toxicity. Recently, the monoclonal antibody rituximab was approved for the treatment of GPA and MPA, providing the first major alternative to cyclophosphamide for induction therapy of AAV. This review explores the emerging role of rituximab in the management of this complex disorder.

  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis/drug therapy
  • Antibodies, Monoclonal, Murine-Derived/therapeutic use
  • Humans
  • Immunosuppressive Agents/therapeutic use
  • Remission Induction/methods
  • Rituximab
Citation (ISO format)
DAIKELER, Thomas et al. The role of rituximab in the treatment of ANCA-associated vasculitides (AAV). In: Schweizerische medizinische Wochenschrift, 2015, vol. 145, p. w14103. doi: 10.4414/smw.2015.14103
Main files (1)
Article (Published version)
ISSN of the journal0036-7672

Technical informations

Creation11/24/2016 1:41:00 PM
First validation11/24/2016 1:41:00 PM
Update time03/15/2023 1:02:12 AM
Status update03/15/2023 1:02:12 AM
Last indexation10/19/2023 2:35:42 AM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack